FibroBiologics, Inc. FBLG
FibroBiologics, Inc. (Nasdaq: FBLG) is a dermatology drug developer. Its lead program, CYWC628, is in Phase 1 for Diabetic foot ulcers (wound healing). Its next catalyst on record is CYWC628: Six-week interim safety and primary efficacy data once 28 patients per arm complete 6 weeks (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CYWC628 — Six-week interim safety and primary efficacy data once 28 patients per arm complete 6 weeks (H2 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CYWC628 (topical allogeneic fibroblast spheroids) | Diabetic foot ulcers; twelve-week Phase 1/2 trial in Australia, dosing began Q2 2026 | cell therapy | Phase 1 |
| CYMS101 (IV allogeneic fibroblasts) | Multiple sclerosis; Phase 1 in 5 participants completed in Mexico, US IND planned | cell therapy | Phase 1 |
| CYPS317 (IV allogeneic fibroblast spheroids) | Psoriasis; Phase 1/2 IND filed December 30, 2025, submission being updated after FDA feedback | cell therapy | Pre-clinical |
| CybroCell | Degenerative disc disease; IND cleared 2018 conditional on master cell bank, trial not started, IND amendment planned | cell therapy | Pre-clinical |
| Thymic organoid, cancer and artificial pancreatic organoid programs | Human longevity / thymic involution; certain cancers; diabetes | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 dermatology companies
- Arcutis Biotherapeutics, Inc. ARQT
- Absci Corp ABSI
- Azitra, Inc. AZTR
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.